EUCTR2011-004583-30-ES进行中（未招募）1 期
A MULTICENTER, PHASE II, RANDOMISED, DOUBLE?BLIND, PLACEBO CONTROLED CLINICAL TRIAL OF THE SUBCUTANEOUS IMMUNOTHERAPY IN DIFFERENT DOSES WITH PARALLEL GROUPS IN SUBJECTS WITH ALLERGIC RHINOCONJUNCTIVITIS +/- ASTHMA SENSITIZED TO DERMATOPHAGOIDES PTERONYSSINUS. - BIA
BIAL Industrial Farmaceutica0 个研究点目标入组 0 人开始时间: 2011年11月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
不适用
STUDY EVALUATING ALX-0061 ADMINISTERED SUBCUTANEOUSLY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS-L93L93PER-048-15Ablynx,6
进行中（未招募）
1 期
A PHASE II, MULTI CENTRE, DOUBLE-BLIND, RANDOMISED, PLACEBO CONTROLLED, DOSE-ESCALATION, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF CK-1827452 IN PATIENTS WITH STABLE HEART FAILURE.EUCTR2006-001871-39-GBCytokinetics, Inc56
进行中（未招募）
1 期
A Multicenter study to evaluate the efficacy and safety of different doses of bimekizumab in subjects with active Ankylosing Spondylitis which is a form of arthritis that primarily affects the spine.MedDRA version: 20.0 Level: PT Classification code 10002556 Term: Ankylosing spondylitis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersAnkylosing SpondylitisEUCTR2016-001102-42-CZCB Biopharma SPR303
进行中（未招募）
1 期
A multicenter study to evaluate the dose response based on the efficacy, safety and tolerability of bimekizumab in subjects with active psoriatic arthritis which is a type of inflammatory arthritis.MedDRA version: 20.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000018188psoriatic arthritisEUCTR2016-001103-23-DECB Biopharma SPR200
进行中（未招募）
1 期
A Multicenter study to evaluate the efficacy and safety of different doses of bimekizumab in subjects with active Ankylosing Spondylitis which is a form of arthritis that primarily affects the spine.MedDRA version: 20.0 Level: PT Classification code 10002556 Term: Ankylosing spondylitis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersAnkylosing SpondylitisEUCTR2016-001102-42-BGCB Biopharma SPR303